Art. -Nr.: HY-169259

HDAC9-IN-1

Kundenbewertung

Based on 1 Customer Validation

HDAC9-IN-1 is a selective class IIa HDAC inhibitor that binds to HDAC9 with an IC₅₀ of 40 nM. HDAC9-IN-1 potently inhibits HDACs 4 and 7 while showing weak activity against HDAC6 (IC₅₀ values: 180 nM (HDAC4), 190 nM (HDAC7), 970 nM (HDAC6)). HDAC9-IN-1 significantly inhibits several human cancer cells, induces apoptosis and DNA damage in human cancer cells, and modulates caspase-related proteins and p38 in human cancer cells. HDAC9-IN-1 can be used for the research of oral cancer, breast cancer, gastric cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 95.13%
Formel: C₂₇H₂₂N₄O₃S
Molecular Weight:482.55

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

HDAC9-IN-1 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

HDAC9

40 nM (IC₅₀)

HDAC4

180 nM (IC₅₀)

HDAC7

190 nM (IC₅₀)

HDAC6

970 nM (IC₅₀)

Caspase-8

Caspase-9

Alle HDAC Isoform-spezifische Produkte anzeigen :

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

In Vitro

HDAC9-IN-1 (compound 7g) (5-30 min) potently inhibits HDAC 9 and class IIa HDACs 4 and 7 while showing weak activity against HDAC 6 and no activity against class I HDACs (IC₅₀ values: 40 nM (HDAC9), 180 nM (HDAC4), 190 nM (HDAC7), 970 nM (HDAC6), >40 μM (class I))^[1].
HDAC9-IN-1 (24 h) inhibits viability of cancer cells and normal lung fibroblasts (IC₅₀ values: 3.0 μM (SCC2095), 8.4 μM (MDA-MB-231), 5.8 μM (SCM-1), 8.0 μM (normal lung fibroblasts))^[1].
HDAC9-IN-1 (1-10 μM; 24-48 h) induces dose- and time-dependent apoptosis in SCC2095 cells^[1].
HDAC9-IN-1 (1-10 μM; 24 h) modulates apoptotic, HDAC substrate, and stress response proteins in SCC2095 cells^[1].
HDAC9-IN-1 (2.5-5 μM; 12-24 h) increases ROS generation accompanied by the increased DNA damage in SCC2095 cells in a time-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

Human oral cancer SCC2095 cells
Concentration:

1 μM, 2.5 μM, 5 μM, 7.5 μM, and 10 μM
Incubation Time:

24 h, 48 h
Result:

Induced apoptosis in a dose- and time-dependent manner: 10 μM for 24 h increased apoptotic cells to 83.6%; 1, 2.5, 5, 7.5, 10 μM for 48 h resulted in apoptosis rates of 29.2%, 35.9%, 44.4%, 78.2%, and 87.1%, respectively.

Western Blot Analysis^[1]

Cell Line:

SCC2095 cells
Concentration:

1 μM, 2.5 μM, 5 μM, 7.5 μM, and 10 μM
Incubation Time:

24 h
Result:

Down-regulated the levels of pro-caspase 8 and up-regulated the levels of cleaved caspase 9.
The levels of HDAC6 substrates such as acetyl-α-tubulin and Hsp90, and two class IIa HDAC-related proteins including
PPARγ and p21 were increased.
Up-regulated the phosphorylation of p38 in a dose-dependent manner in SCC2095 cells.
Increased the phosphorylation of Histone H2A.X, a DNS damage biomarker.

Chemical Information

Appearance Solid
Molecular Weight 482.55
Formel C₂₇H₂₂N₄O₃S
Color Light brown to brown
SMILES

N/C(C1=CC2=C(SC3=CC=CC=C3N2CC4=CC=C(C(C5=CC=CC=C5)=C4)C(NO)=O)C=C1)=N\O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (103.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0723 mL

10.3616 mL

20.7232 mL

5 mM

0.4145 mL

2.0723 mL

4.1446 mL

10 mM

0.2072 mL

1.0362 mL

2.0723 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hsu KC, et al. Synthesis and biological evaluation of ortho-phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases. J Enzyme Inhib Med Chem. 2024;39(1):2406025. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0723 mL	10.3616 mL	20.7232 mL	51.8081 mL
	5 mM	0.4145 mL	2.0723 mL	4.1446 mL	10.3616 mL
	10 mM	0.2072 mL	1.0362 mL	2.0723 mL	5.1808 mL
	15 mM	0.1382 mL	0.6908 mL	1.3815 mL	3.4539 mL
	20 mM	0.1036 mL	0.5181 mL	1.0362 mL	2.5904 mL
	25 mM	0.0829 mL	0.4145 mL	0.8289 mL	2.0723 mL
	30 mM	0.0691 mL	0.3454 mL	0.6908 mL	1.7269 mL
	40 mM	0.0518 mL	0.2590 mL	0.5181 mL	1.2952 mL
	50 mM	0.0414 mL	0.2072 mL	0.4145 mL	1.0362 mL
	60 mM	0.0345 mL	0.1727 mL	0.3454 mL	0.8635 mL
	80 mM	0.0259 mL	0.1295 mL	0.2590 mL	0.6476 mL
	100 mM	0.0207 mL	0.1036 mL	0.2072 mL	0.5181 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

HDAC9-IN-1

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

HDAC9-IN-1 Related Classifications

HY-169259 Related Classifications